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BACKGROUND: The risk of vertical transmission of
severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection remains unknown. Positive
reverse-transcription polymerase chain reaction (RT-
PCR) test results for SARS-CoV-2 infection in neonates
and placental tissue have been reported, and immuno-
globulin M antibodies have been detected in neonates
born to mothers with infection.
CASES: The first case is a woman at 22 3/7 weeks of
gestation with coronavirus disease 2019 (COVID-19)
who was admitted to the intensive care unit. In the
second case, the patient remained at home with mild
symptoms, starting at 20 weeks of gestation. In both
cases, fetal skin edema was observed on ultrasound
examination while maternal SARS-COV-2 RT-PCR test
results were positive and resolved when maternal
SARS-COV-2 RT-PCR test results became negative.
The RT-PCR test result for SARS-CoV-2 in amniotic fluid
was negative in both cases. The two pregnancies are
ongoing and uneventful.
CONCLUSION: Transient fetal skin edema noted in
these two patients with COVID-19 in the second tri-
mester may represent results of fetal infection or altered
fetal physiology due to maternal disease or may be
unrelated to the maternal illness.
(Obstet Gynecol 2020;136:1016–20)
DOI: 10.1097/AOG.0000000000004059
Coronavirus disease 2019 (COVID-19) is a highlyinfectious disease caused by severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2). Spain
reported its first case on January 31, 2020, and more
than 241,000 confirmed cases and 27,100 deaths have
been reported.1
Some maternal infections during pregnancy are
associated with poor perinatal outcomes and fetal
anomalies. In infections such as cytomegalovirus or
Zika virus, gestational age at the time of maternal
infection plays a role in the risk of both intrauterine
infection and severe sequelae.2,3 In SARS-CoV-2 infec-
tion, there is a paucity of reports of pregnancy out-
comes with infection before the third trimester.
The risk of maternal–fetal transmission of SARS-
CoV-2 infection remains controversial. Severe acute
respiratory syndrome coronavirus 2 has been de-
tected in placental swabs or biopsies in five cases,
but not in amniotic fluid.4–7 However, it is unknown
whether the virus, the immune response it causes, or
the gestational age at which the infection occurs may
have consequences for the fetus.8
Teaching Point
1. Maternal coronavirus disease 2019 (COVID-19)
might have an effect on the fetus during pregnancy.
From the Maternal Fetal Medicine Unit, Department of Obstetrics, the
Microbiology Department, the Pediatric Critical Care Department, and the
Department of Infectious Diseases, Vall d’Hebron Barcelona Hospital Campus,
Universitat Autònoma de Barcelona, Barcelona, and the Red Española de In-
vestigación en Patología Infecciosa (REIPI), Instituto de Salud Carlos III, Ma-
drid, Spain.
Funding was provided for the Gesta-COVID19 Study by Instituto de Salud
Carlos III (ISCIII) (PR(AMI)181/2020) (ISCIII’s reference: COV20/00188).
The authors thank all the members of the Gesta-COVID19 Collaboration Group
for their help in data collection for the Gesta-COVID19 Study, and Erika Bokor
for the English language correction of the manuscript.
Each author has confirmed compliance with the journal’s requirements for
authorship.
Published online ahead-of-print July 7, 2020.
Corresponding author: Carlota Rodó, MD, PhD, Department of Obstetrics, Vall
d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron, Barcelona, Spain;
email: crodo@vhebron.net.
Financial Disclosure
The authors did not report any potential conflicts of interest.
© The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-
access article distributed under the terms of the Creative Commons Attribution-
Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is
permissible to download and share the work provided it is properly cited. The
work cannot be changed in any way or used commercially without permission
from the journal.
ISSN: 0029-7844/20
1016 VOL. 136, NO. 5, NOVEMBER 2020 OBSTETRICS & GYNECOLOGY
Herein, we present two cases of unexplained fetal
skin edema in two pregnant women diagnosed with
COVID-19 during the second trimester of pregnancy.
CASE 1
A 50-year-old primigravid woman at 22 6/7 weeks of
gestation presented to the emergency department at Vall
d’Hebron University Hospital (Barcelona, Spain) with a 7-
day history of dry cough and fever. She was living with her
mother, who had tested positive for SARS-CoV-2 infection
on reverse-transcription polymerase chain reaction (RT-
PCR) testing. The patient was a former smoker, had no
relevant medical history, and was receiving 150 mg of
acetylsalicylic acid owing to a high risk of early-onset
preeclampsia. Her gestation was conceived by in vitro
fertilization with egg donation and had had an uneventful
course. No genetic tests had been performed during the
pregnancy. Physical examination revealed a body mass
index (BMI, calculated as weight in kilograms divided
by height in meters squared) of 25.4, blood pressure
125/64 mm Hg, temperature 37˚C, and respiratory rate
of 30 breaths per minute, with a hemoglobin saturation
by pulse oximetry of 93% on room air. Blood tests per-
formed at admission showed lymphopenia and
interleukin-6 (IL-6) and D-dimer levels above the normal
range (Table 1).
A chest radiograph showed conspicuous bilateral
ground glass opacities, and the patient tested positive for
SARS-CoV-2 infection on RT-PCR testing of oropharyngeal
and nasopharyngeal swabs (Allplex 2019-nCoV assay). A
COVID-19 bilateral pneumonia was diagnosed, and the
patient was admitted and put on azithromycin, lopinavir-
ritonavir, and hydroxychloroquine medications (day 0).
Obstetric ultrasound examination at admission showed no
fetal anomalies, normal Doppler parameters, and a normal
amount of amniotic fluid. The day after admission (day 1),
the patient’s condition worsened and she was transferred to
the intensive care unit (ICU), where she underwent intuba-
tion for mechanical ventilation on day 2 (23 1/7 weeks of
gestation). Fetal prognosis was estimated to be poor owing
to gestational age. After discussion with the mother, expec-
tant management of the pregnancy was decided on by
a multidisciplinary team (obstetricians and critical care
and infectious disease specialists). Elective delivery was
accorded with the patient before intubation if deterioration
persisted. Blood tests were performed daily, and pro-
inflammatory markers related to COVID-19 severity (IL-6
and D-dimer) were also monitored (Fig. 1).9 The result of
the SARS-CoV-2 RT-PCR test in peripheral blood was
negative.
Fetal well-being scans (Siemens Acuson NX2) were
conducted daily by the ICU team to check fetal heart rate
and weekly by a fetal medicine specialist to assess fetal
growth, Doppler parameters, and the amount of amniotic
fluid and to detect any potential abnormalities. Fetal heart
rate was always within the normal range, without episodes
of tachycardia or bradycardia.
On day 6 (23 5/7 weeks of gestation), fetal skin edema
was observed with no ascites, hydrothorax, thickened
placenta, or other signs of hydrops fetalis. Edema was
generalized, but it was more evident in the scalp and
trunk. A detailed survey for anomalies and fetal echocar-
diography were performed, showing no abnormal results.
The same findings persisted on day 10 (24 2/7 weeks), and
no structural anomalies were found (Fig. 2). Doppler ex-
aminations of the umbilical artery, middle cerebral artery,
ductus venosus, and uterine arteries were also within nor-
mal limits. Maternal indirect antiglobulin and serologic
tests were obtained, being negative for cytomegalovirus,
varicella zoster virus, parvovirus B19, Toxoplasma gondii,
herpes virus, and rubella. An amniocentesis was
Table 1. Patients’ Relevant Clinical Findings
Clinical Characteristics Patient 1 Patient 2
Age (y) 50 30
Ethnicity White Latin American
Nuchal translucency in 1st trimester (mm) 1.28 2.3
Gestational age at COVID-19 diagnosis (wk) 22.6 20.1
Time from symptom onset to fetal edema (d) 13 10
Maternal serum IL-6* level at COVID-19 diagnosis (pg/mL) 76.47 16.22
Maternal serum D-dimer* level at COVID-19 diagnosis (ng/mL) 576 953
Gestational age at fetal edema diagnosis (wk) 23.5 21.2
Maternal serum IL-6 level at fetal edema diagnosis (pg/mL) 409.5 3.59
Maternal serum D-dimer level at fetal edema diagnosis (ng/mL) 2,190 373
Time RT-PCR remained positive for SARS-CoV-2 infection (d) 17 22
Fetal edema duration (d) 11 14
RT-PCR test result for SARS-CoV-2 in maternal serum Negative Negative
IL-6 level in amniotic fluid* (pg/mL) 345.18 109.4
COVID-19, coronavirus disease 2019; IL-6, interleukin-6; RT-PCR, reverse-transcription polymerase chain reaction; SARS-CoV-2, severe
acute respiratory syndrome coronavirus 2.
* Reference ranges: serum IL-6: 0–4.3 pg/mL; D-dimer: 0–243 ng/mL; IL-6 in amniotic fluid: median values ranging from 150.5 to 339 pg/
mL.10
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performed on day 12. The results of the genetic test
(Quantitative Genomic Hybridization Array, 8 60K Agilent
G4827A CGH (ISCA v2 array) were normal. The RT-PCR
test result for SARS-CoV-2 in amniotic fluid was negative,
and the IL-6 level in amniotic fluid was within the normal
range.10 Tests in amniotic fluid were negative for cytomeg-
alovirus, varicella zoster virus, parvovirus B19, T gondii,
and sexually transmitted infectious agents (Chlamydia tra-
chomatis, Neisseria gonorrhoeae, Mycoplasma hominis,
Ureaplasma parvum, Mycoplasma genitalium, Ureaplas-
ma urealyticum, and Trichomonas vaginalis).
One week later (day 17, 25 2/7 weeks of gestation), the
maternal condition improved: PaO2 progressively increased,
and oxygen supplementation requirements lowered. Pro-
inflammatory markers decreased, and the result of the
SARS-CoV-2 RT-PCR test on oropharyngeal and nasopharyn-
geal swabs was negative. Simultaneously, the fetal edema
had almost disappeared on ultrasound examination (Fig. 2).
CASE 2
A 30-year-old primigravid woman at 20 1/7 weeks of gestation
with no relevant medical history presented to the emergency
department (day 0) with cough and fever in the previous 48
hours. She was living with her husband and her parents, and
all three had tested positive for SARS-CoV-2 infection. Her
gestation had had an uneventful course. Physical examination
revealed a BMI of 32, blood pressure 130/71 mm Hg,
temperature of 37.5˚C, respiratory rate 16 breaths
per minute, and a hemoglobin saturation of 99% on room
air. The results of blood tests performed at admission are
shown in Table 1. Chest radiography showed no anomalies,
and the patient tested positive for SARS-CoV-2 infection on
RT-PCR of oropharyngeal and nasopharyngeal swabs. She was
diagnosed with mild COVID-19, and she was discharged with
no medication to home isolation. Maternal well-being was
assessed daily by phone calls, and no deterioration requiring
Fig. 1. Proinflammatory marker
evolution during admission in case
1. Fetal skin edema was observed
between days 6 and 17 and is de-
limited by a grey area. Intensive
care unit (ICU) admission and
amniocentesis were on days 2 and
12, respectively.
Garcia-Manau. Fetal Skin Edema in
Pregnant Women With COVID-19.
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Fig. 2. Fetal skin edemas. Fetal
ultrasound examinations. Case 1:
skin edema in transcerebellar (A)
and transthoracic (B) planes and its
resolution (C). Case 2: skin edema
in transthoracic (D) and midsagittal
face (E) planes and its resolution
(F).
Garcia-Manau. Fetal Skin Edema in
Pregnant Women With COVID-19.
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hospital admission was observed. On day 8 (21 2/7 weeks of
gestation), an ultrasound examination was performed, detect-
ing an isolated mild fetal skin edema with no other abnormal-
ities (Fig. 2). Fetal echocardiography and Doppler parameters
were also within normal limits. Fetal heart rate was within the
normal range, and no episodes of tachycardia or bradycardia
were recorded. Middle cerebral artery velocity was within the
normal range. Maternal indirect antiglobulin and serologic
tests were obtained, with negative results. Nasopharyngeal
RT-PCR test results remained positive, and RT-PCR test results
in peripheral blood were negative. The IL-6 level in maternal
serum was within the normal range, and D-dimer levels were
slightly elevated (Table 1). An amniocentesis was performed,
and the RT-PCR assay of the amniotic fluid was negative for
SARS-CoV-2 infection. Result s of genetic tests (Quantitative
Genomic Hybridization Array) and tests for congenital infec-
tions (cytomegalovirus, varicella zoster virus, parvovirus B19,
T gondii, Chlamydia trachomatis, N gonorrhoeae, M hominis,
U parvum, M genitalium, U urealyticum, and T vaginalis) in
amniotic fluid were negative. The IL-6 level in amniotic fluid
was normal.10 On day 22 (23 2/7 weeks of gestation), fetal
edema had disappeared after the SARS-CoV-2 RT-PCR test
result was negative.
At the time of submission, both women are still
pregnant. Their gestations are being closely followed-up,
with a complete resolution of the fetal edema, and no other
fetal anomalies have been reported.
DISCUSSION
Two cases of fetal transient skin edema in pregnant
women with COVID-19 in their second trimester of
pregnancy are described. In case 1, the patient was
admitted to the ICU and fetal edema followed a time
course parallel to the maternal respiratory condition
and the pro-inflammatory markers; the edema dis-
appeared with maternal recovery. Patient 2 remained
at home with mild symptoms and did not require
hospital admission. Pro-inflammatory markers were
lower, and the edema was milder and it also dis-
appeared with maternal improvement. In both cases,
viremia and amniotic fluid RT-PCR test results were
negative for SARS-CoV-2 infection.
There is still inconclusive evidence of transpla-
centally acquired fetal infection reported in the
literature. A study investigated the expression of
SARS-CoV-2 receptors, identified as angiotensin-
converting enzyme 2, in human maternal–fetal inter-
face and the main fetal organs. The authors conclude
that angiotensin-converting enzyme 2 is widely pres-
ent in the human placenta and in the main fetal or-
gans.11 Another article describes a second-trimester
miscarriage in a woman diagnosed with COVID-19
in which placental and amniotic membranes tested
positive for SARS-CoV-2 infection.6 In another study,
three cases of detection of SARS-CoV-2 RNA in pla-
cental or membrane samples are also described;
although none of the neonates tested positive.4
Recently, the first two cases of positive RT-PCR test
results for SARS-CoV-2 infection in mother, neonate,
and placental tissues have been reported.5 However,
none of these studies demonstrate fetal abnormalities
or the presence of the virus in amniotic fluid or in
cord blood.
Current protocols recommend, for safety reasons,
delaying ultrasound scans while pregnant women are
positive for SARS-CoV-2 infection, which may result
in lack of observation of transient fetal abnormali-
ties.12,13 However, at our center we are scanning preg-
nant women weekly in the framework of an
Institutional Review Board–approved observational
study (PR(AMI)181/2020), which includes microbio-
logical sampling and ultrasound examinations in
pregnant women with COVID-19. During the pan-
demic, we performed 31 ultrasound examinations
on pregnant women with COVID-19, and fetal skin
edema was seen in two cases (6.5%; 95% CI 1.8–
20.7%).
Some patients with COVID-19 develop a rapid
deterioration related to a cytokine storm syndrome
due to a massive, virally driven hyperinflamma-
tion.14,15 It has been demonstrated that maternal cy-
tokines during pregnancy can lead to a failure in
multiple fetal organ systems.16 The fetal edema
described in case 1 appeared when the highest mater-
nal serum IL-6 concentrations were noted and while
D-dimer was rapidly increasing. By contrast, its res-
olution was preceded by a progressive decrease in
both serum IL-6 and D-dimer values; the lowest con-
centrations were noted when the edema had disap-
peared on day 17, coinciding with a negative SARS-
CoV-2 RT-PCR test result (Fig. 1). In case 2, edema
was observed with a low pro-inflammatory status, as
IL-6 levels were within the normal range. The IL-6
levels in amniotic fluid were normal in both cases.
For this reason, we believe that SARS-CoV-2 might
have an effect on the fetus, regardless of the pro-
inflammatory maternal profile.
Despite the overwhelming amount of data gener-
ated since the beginning of the COVID-19 outbreak,
many questions about the virus–host interactions
remain unanswered. Pregnant women represent
a small subgroup of patients with COVID-19, and
there is a dearth of data about the potential effects
of the virus on the fetus.
This report has several limitations. Firstly, two
cases are insufficient to draw out significant conclu-
sions. Fetal edema is a nonspecific finding and often
idiopathic. Considering other congenital infections, the
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time interval from infection to fetal edema was shorter
than expected, and fetal edema is not a common
finding in cases of intraamniotic inflammation or
chorioamnionitis. We, therefore, cannot state that fetal
skin edema was caused by SARS-CoV-2 infection,
despite the correlation between the disappearance of
the edema and the negative test results for the virus.
Secondly, the interpretation of a negative result on RT-
PCR test for detection of SARS-CoV-2 infection in
amniotic fluid is unknown, and the possibility of the
virus testing negative in utero cannot be excluded,
because this has been demonstrated for other
viruses.7,17
To conclude, we report a fetal complication
potentially related to COVID-19 in pregnant women.
Given these findings and the lack of reports of
COVID-19 in the first and second trimesters, a close
follow-up of these pregnancies may help to under-
stand the effect on the fetus.
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